(FDA release) – Azurity Pharmeceuticals Inc. is voluntarily recalling a lot of Zenzedi CII 30 mg tablets at the consumer level, due to the discovery of tablets of Carbinoxamine (CARBIN-OX-UH-MINE) Maleate (MAL-EE-AYE-T) in a bottle of the product.
Patients using the carbinoxamine tablets tend to experience undertreatment of their symptoms, which results in funcional impairment and increases risk of accidents and injury.. Unknowingly consuming carbinoxamine may cause the following adverse effects – drowsiness, sleepiness, central nervous system depression, increased eye pressure, enlarged prostate obstruction, and thyroid disorder.
For more information on the recalled product, visit this story on the web at hilinetoday dot com.
————————————————————
Additional information
Zenzedi CII (dextroamphetamine sulfate tablets) 30 mg recalled Lot# F230169A)
Carbinoxamine Maleate tablets found in bottle of Zenzedi CII by a pharmacist in Nebraska. The incident caused the manufacturer (Azurity Pharmaceuticals Inc.) to open a product complaint and begin investigation.
